Patents by Inventor Marko Mihovilovic
Marko Mihovilovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210047322Abstract: Provided herein are novel pyrazoloquinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis; depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.Type: ApplicationFiled: October 23, 2020Publication date: February 18, 2021Inventors: Lih-Chu Chiou, James Cook, Margot Ernst, Pi-Chuan Fan, Daniel Knutson, Matheus Meirelles, Marko Mihovilovic, Werner Sieghart, Zdravko Varagic, Ranjit Verma, Laurin Wimmer, Christopher Witzigmann, David Chan Bodin Siebert, Miroslav M. Savic
-
Patent number: 10865203Abstract: Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis; depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.Type: GrantFiled: June 3, 2016Date of Patent: December 15, 2020Assignees: UWM Research Foundation, Inc., Medical University of ViennaInventors: James Cook, Daniel Knutson, Marko Mihovilovic, Laurin Wimmer
-
Publication number: 20180134698Abstract: Provided herein are novel pyrazolo-quinolinone compounds and method of using such compounds to treat disorders such as neuropsychiatric disorders with sensorimotor gating deficits, such as schizophrenia, tic disorders, attention deficit hyperactivity disorder, obsessive compulsive disorder, panic disorder, Huntington's disease and nocturnal enuresis;depression; temporomandibular myofascial pain; disorders of trigeminal nerve, such as trigeminal neuralgia and trigeminal neuropathy; migraine; and tinnitus.Type: ApplicationFiled: June 3, 2016Publication date: May 17, 2018Inventors: Lih-Chu Chiou, James Cook, Margot Ernst, Pi-Chuan Fan, Daniel Knutson, Matheus Meirelles, Marko Mihovilovic, Werner Sieghart, Zdravko Varagic, Ranjit Verma, Laurin Wimmer, Christopher Witzigmann, David Chan Bodin Siebert, Miroslav M. Savic
-
Patent number: 9902981Abstract: A process for the production of furan derivatives from D-glucose, wherein A) D-glucose is converted into D-fructose in an enzymatic process, wherein redox cofactors are used and regenerated, whereby, as a result of at least two further enzymatically catalyzed redox reactions proceeding in the same reaction batch, one of the two redox cofactors accumulates in its reduced form and, respectively, the other one in its oxidized form, whereby D-glucose is converted into D-fructose, involving two or more oxidoreductases, and B) D-fructose is converted into furan derivatives, and the use of furan derivatives produced in this manner.Type: GrantFiled: February 6, 2013Date of Patent: February 27, 2018Assignee: ANNIKKI GMBHInventors: Ortwin Ertl, Nicole Staunig, Marta Sut, Bernd Mayer, Marko Mihovilovic, Michael Schön, Johanna Hölbling
-
Publication number: 20170157301Abstract: A compound of formula (II), and a method of preparation thereof, for use as a smooth muscle cell (SMC) proliferation-inhibiting drug: wherein: R1 to R6 are —H, —F, —CH3, —CF3, —CF2CH3, —OCH3, —COCH3, —C4H9, —COOC2H5, or —C6H5, or two vicinal residues from R1 to R6 form a saturated or unsaturated carbocyclic ring together with the two carbon atoms to which they are attached; R7 is OH, allyloxy, propargyl-oxy, 2,2-dimethylpropanoyloxy (pivaloyloxy), butanoyloxy, 3-methylbutanoyloxy, 2-buten-oyloxy, 2-methyl-2-butenoyloxy, 3-methyl-2-butenoyloxy, isopentanoyloxy, 2-ethylbutanoyl-oxy, 3,3-dimethylbutanoyloxy, cyclopropylcarbonyloxy, cyclobutylcarbonyloxy, cyclo-pentylcarbonyloxy, cyclopentenylcarbonyloxy, cyclohexylcarbonyloxy, cyclo-hexenylcarbonyloxy, adamantylethanoyloxy, 3-phenylpropenoyloxy (cinnamyloyloxy), 2-methylbenzoyloxy, or naphthoyloxy; wherein, in ring A and/or B, one or more carbon ring atoms are optionally replaced by heteroatoms; wherein the compounds of formula (II) are obtained by combiningType: ApplicationFiled: June 24, 2015Publication date: June 8, 2017Applicants: TECHNISCHE UNIVERSITÄET WIEN, UNIVERSITAET INNSBRUCKInventors: Marko MIHOVILOVIC, Thomas LINDER, Verena M. DIRSCH, Atanas ATANASOV, David BERNHARD, Herrmann STUPPNER, Stefan SCHWAIGER
-
Publication number: 20170137396Abstract: Process for the selective production of oxidized furan derivatives starting from 5-hydroxymethyl-2-furfural in the presence of a solvent, an oxidation agent, a catalyst, and optionally a base, which process is characterized in that the oxidation process is carried out continuously in flow, and there are provided means for varying reaction parameters.Type: ApplicationFiled: June 17, 2015Publication date: May 18, 2017Inventors: Marko Mihovilovic, Michael Schön, Stefan Dochev
-
Patent number: 9611457Abstract: A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently —NR4—or —O—, R4 is hydrogen or C1-6-alkyl; R1 is hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C1-6-alkylamino, or di-C1-6-alkylamino, the C1-6-alkyl or -alkoxy residue being optionally substituted with one or more R5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; R2 is hydrogen, aryl, heteroaryl, or C1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more R1 substituents, and where the C1-6-alkyl is optionally further substituted with one or more R5 substituents; and R3 is selected from hydrogen, halo, NR4R7, OR7, SR7, and R7, where the same options apply for R7 as for R2; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.Type: GrantFiled: September 21, 2012Date of Patent: April 4, 2017Assignee: TECHNISCHE UNIVERSITAET WIENInventors: Marko Mihovilovic, Michael Schnuerch, Karlheinz Hilber, Xaver Koenig, Thomas Linder, Agnes Mike
-
Patent number: 9475787Abstract: A process for the production of furan derivatives from carbohydrates in the presence of an acidic catalyst, characterized in that N-methylpyrrolidone is used as a solvent and that the acidic catalyst is homogeneous.Type: GrantFiled: September 2, 2013Date of Patent: October 25, 2016Assignee: Annikki GMBHInventors: Marko Mihovilovic, Michael Schön, Johanna Hölbling
-
Publication number: 20150218118Abstract: A process for the production of furan derivatives from carbohydrates in the presence of an acidic catalyst, characterized in that N-methylpyrrolidone is used as a solvent and that the acidic catalyst is homogeneous.Type: ApplicationFiled: September 2, 2013Publication date: August 6, 2015Inventors: Marko Mihovilovic, Michael Schön, Johanna Hölbling
-
Patent number: 8986994Abstract: Provided are compounds of formula (I) and/or salts thereof, of the class of substituted pyridines and pyrimidines, useful for inducing cardiomyogenesis, a process for producing cardiomyocyte-like cells from mammalian cells by culturing mammalian cells in the presence of the compound of formula (I), the pharmaceutical use of compounds of formula (I) for producing cardiomyocyte-like cells from omnipotent, pluripotent, or lineage committed mammalian cells, and the use of thus produced cardiomyocyte-like cells for treating disorders associated with impaired function of the heart.Type: GrantFiled: December 28, 2010Date of Patent: March 24, 2015Assignee: Technische Universitaet WienInventors: Marko Mihovilovic, Michael Schnuerch, Moumita Koley, Karlheinz Hilber, Xaver Koenig
-
Publication number: 20150010965Abstract: A process for the production of furan derivatives from D-glucose, wherein A) D-glucose is converted into D-fructose in an enzymatic process, wherein redox cofactors are used and regenerated, whereby, as a result of at least two further enzymatically catalyzed redox reactions proceeding in the same reaction batch, one of the two redox cofactors accumulates in its reduced form and, respectively, the other one in its oxidized form, whereby D-glucose is converted into D-fructose, involving two or more oxidoreductases, and B) D-fructose is converted into furan derivatives, and the use of furan derivatives produced in this manner.Type: ApplicationFiled: February 6, 2013Publication date: January 8, 2015Inventors: Ortwin Ertl, Nicole Staunig, Marta Sut, Bernd Mayer, Marko Mihovilovic, Michael Schön, Johanna Hölbling
-
Publication number: 20140234965Abstract: A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently —NR4— or —O—, R4 is hydrogen or C1-6-alkyl; R1 is hydroxy, C1-6-alkyl, C1-6-alkoxy, carboxy, C1-6-alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C1-6-alkylamino, or di-C1-6-alkylamino, the C1-6-alkyl or -alkoxy residue being optionally substituted with one or more R5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; R2 is hydrogen, aryl, heteroaryl, or C1-6-alkyl, the aryl or heteroaryl residue being optionally substituted with one or more R1 substituents, and where the C1-6-alkyl is optionally further substituted with one or more R5 substituents; and R3 is selected from hydrogen, halo, NR4R7, OR7, SR7, and R7, where the same options apply for R7 as for R2; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.Type: ApplicationFiled: September 21, 2012Publication date: August 21, 2014Applicants: MEDIZINISCHE UNIVERSITAET WIEN, TECHNISCHE UNIVERSITAET WIENInventors: Marko Mihovilovic, Michael Schnuerch, Karlheinz Hilber, Xaver Koenig, Thomas Linder, Agnes Mike
-
Publication number: 20140208772Abstract: A device is provided for cooling or heating vessels and containers for carrying out chemical or physical reactions. The device includes the following components in a vertical direction from top to bottom: a heat-conductive cooling or heating plate; at least one Peltier element equipped with electrical connections; optionally at least one heat-conductive separator plate between two Peltier elements respectively; a heat-conductive thermoblock, through which one or more fluid channels pass, for dissipation and supply of heat from and to the at least one Peltier element; and an external control unit for the at least one Peltier element. The components rest on top of one another and are therefore in direct planar contact with one another.Type: ApplicationFiled: July 4, 2012Publication date: July 31, 2014Applicant: TECHNISCHE UNIVERSITÄT WIENInventors: Michael Schön, Marko Mihovilovic, Michael Schnürch
-
Publication number: 20120294835Abstract: Provided is a compound of formula (I), and/or salt thereof, wherein the radicals have various meanings, a process for producing cardiomyocyte-like cells from mammalian cells by culturing mammalian cells in the presence of the compound of formula (I), the pharmaceutical use of compounds of formula (I) for producing cardiomyocyte-like cells from omnipotent, pluripotent, or lineage committed mammalian cells, and the use of thus produced cardiomyocyte-like cells for treating disorders associated with impaired function of the heart.Type: ApplicationFiled: December 28, 2010Publication date: November 22, 2012Applicants: MEDIZINISCHE UNIVERSITAET WIEN, TECHNISCHE UNIVERSITAET WIENInventors: Marko Mihovilovic, Michael Schnuerch, Moumita Koley, Karlheinz Hilber, Xaver Koenig